Pfizer Operating Expenses 2010-2024 | PFE
Pfizer annual/quarterly operating expenses history and growth rate from 2010 to 2024. Operating expenses can be defined as the sum of all operating expenses for the given industry.
- Pfizer operating expenses for the quarter ending September 30, 2024 were $12.743B, a 23.52% decline year-over-year.
- Pfizer operating expenses for the twelve months ending September 30, 2024 were $54.657B, a 7.87% decline year-over-year.
- Pfizer annual operating expenses for 2023 were $58.274B, a 10.88% decline from 2022.
- Pfizer annual operating expenses for 2022 were $65.386B, a 5.71% increase from 2021.
- Pfizer annual operating expenses for 2021 were $61.855B, a 85.19% increase from 2020.
Pfizer Annual Operating Expenses
(Millions of US $) |
| 2023 |
$58,274 |
| 2022 |
$65,386 |
| 2021 |
$61,855 |
| 2020 |
$33,401 |
| 2019 |
$34,195 |
| 2018 |
$35,153 |
| 2017 |
$38,824 |
| 2016 |
$40,679 |
| 2015 |
$37,027 |
| 2014 |
$36,356 |
| 2013 |
$36,400 |
| 2012 |
$39,393 |
| 2011 |
$47,068 |
| 2010 |
$51,753 |
| 2009 |
$38,310 |
Pfizer Quarterly Operating Expenses
(Millions of US $) |
| 2024-09-30 |
$12,743 |
| 2024-06-30 |
$12,280 |
| 2024-03-31 |
$10,777 |
| 2023-12-31 |
$18,857 |
| 2023-09-30 |
$16,662 |
| 2023-06-30 |
$10,813 |
| 2023-03-31 |
$11,942 |
| 2022-12-31 |
$19,908 |
| 2022-09-30 |
$13,695 |
| 2022-06-30 |
$15,523 |
| 2022-03-31 |
$16,260 |
| 2021-12-31 |
$20,847 |
| 2021-09-30 |
$17,888 |
| 2021-06-30 |
$13,293 |
| 2021-03-31 |
$9,827 |
| 2020-12-31 |
$10,724 |
| 2020-09-30 |
$7,829 |
| 2020-06-30 |
$7,792 |
| 2020-03-31 |
$7,056 |
| 2019-12-31 |
$6,771 |
| 2019-09-30 |
$9,722 |
| 2019-06-30 |
$8,998 |
| 2019-03-31 |
$8,704 |
| 2018-12-31 |
$7,172 |
| 2018-09-30 |
$9,534 |
| 2018-06-30 |
$9,490 |
| 2018-03-31 |
$8,957 |
| 2017-12-31 |
$11,396 |
| 2017-09-30 |
$9,504 |
| 2017-06-30 |
$9,155 |
| 2017-03-31 |
$8,769 |
| 2016-12-31 |
$11,871 |
| 2016-09-30 |
$10,024 |
| 2016-06-30 |
$9,670 |
| 2016-03-31 |
$9,114 |
| 2015-12-31 |
$12,213 |
| 2015-09-30 |
$8,729 |
| 2015-06-30 |
$8,258 |
| 2015-03-31 |
$7,827 |
| 2014-12-31 |
$10,971 |
| 2014-09-30 |
$8,679 |
| 2014-06-30 |
$8,823 |
| 2014-03-31 |
$7,883 |
| 2013-12-31 |
$10,515 |
| 2013-09-30 |
$8,659 |
| 2013-06-30 |
$8,686 |
| 2013-03-31 |
$8,540 |
| 2012-12-31 |
$10,291 |
| 2012-09-30 |
$9,210 |
| 2012-06-30 |
$9,100 |
| 2012-03-31 |
$10,792 |
| 2011-12-31 |
$9,526 |
| 2011-09-30 |
$12,521 |
| 2011-06-30 |
$12,464 |
| 2011-03-31 |
$12,557 |
| 2010-12-31 |
$13,575 |
| 2010-09-30 |
$12,232 |
| 2010-06-30 |
$12,931 |
| 2010-03-31 |
$13,015 |
| 2009-12-31 |
$15,836 |
| 2009-09-30 |
$7,490 |
| 2009-06-30 |
$7,863 |
| 2009-03-31 |
$7,121 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$142.241B |
$58.496B |
|
Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines.
|
